PMID: 8944747Nov 11, 1996Paper

The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing lipoproteins

Biochimica Et Biophysica Acta
T Nishimaki-MogamiA Takahashi

Abstract

The role of phosphatidylcholine (PC) synthesis via the phosphatidylethanolamine (PE) methylation pathway in the secretion of very low density lipoproteins (VLDL) by cultured rat hepatocytes has been investigated by determining the effects of inhibitors. We have shown that bezafibrate and clofibric acid, known hypolipidemic agents, are potent inhibitors of PE methylation (see accompanying paper by Nishimaki-Mogami et al. (1996) Biochim. Biophys. Acta 1304). In hepatocytes incubated with ethanolamine, which maintained cellular PE levels and PE methylation activity, bezafibrate (200 microM) decreased the secretion of triacylglycerol (TG), PC, apolipoproteins B48, and E in VLDL by 50-75%. In contrast, bezafibrate at this concentration had marginal effect on VLDL secretion (83-115% of control) by hepatocytes that had been cultured in the absence of ethanolamine. In these cells PE levels and PE methylation activity had decreased by approx. 40%. VLDL secretion was decreased at concentrations similar to those required to inhibit PE methylation, and was accompanied by an increase in cellular TG levels. The same ethanolamine-dependent effects were produced by clofibric acid and also by 3-deazaadenosine (DZA), an inhibitor of cellular met...Continue Reading

References

May 1, 1976·The Journal of Cell Biology·C A AlexanderR J Havel
Jun 15, 1979·Biochemical Pharmacology·P K Chiang, G L Cantoni
Jul 1, 1978·Public Health·L R Ford
May 9, 1977·Biochemical and Biophysical Research Communications·B Akesson
Jan 23, 1989·Biochimica Et Biophysica Acta·M M HussainV I Zannis
Jan 1, 1988·Progress in Lipid Research·D E Vance, N D Ridgway
Jan 17, 1984·Biochimica Et Biophysica Acta·D E VanceD Steinberg
May 1, 1993·Biochemical Society Transactions·J BorénS O Olofsson
Apr 1, 1993·The Journal of Clinical Investigation·H WangE A Fisher
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·O I BuiakovaF L Margolis
May 11, 2004·The Journal of Organic Chemistry·Emília ValenteJim Iley
Aug 14, 2008·Proceedings of the National Academy of Sciences of the United States of America·R SilvaA G Suits
Jul 21, 2009·The Journal of Biological Chemistry·Guorui HuangDaniel S Greenspan

❮ Previous
Next ❯

Citations

Apr 1, 2010·Indian Journal of Clinical Biochemistry : IJCB·P V RajN Udupa
Oct 2, 2012·Indian Journal of Clinical Biochemistry : IJCB·P Vasanth RajN Udupa
Jan 15, 1999·Atherosclerosis·M M van Greevenbroek, T W de Bruin
May 9, 1998·Toxicology Letters·T MurakamiK Hirano
Dec 16, 1997·Proceedings of the National Academy of Sciences of the United States of America·C J WalkeyD E Vance
Mar 28, 2009·FEBS Letters·Rima Obeid, Wolfgang Herrmann
Apr 24, 2003·Critical Reviews in Toxicology·Lutz W D WeberAndreas Stampfl
Apr 29, 1998·Current Opinion in Lipidology·D E Vance, C J Walkey
Jan 29, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Bernd C SchwahnRima Rozen
Nov 15, 2002·The Journal of Biological Chemistry·David J ShieldsDennis E Vance
Jul 5, 2003·The Journal of Biological Chemistry·David J ShieldsDennis E Vance

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.